Cancer Medtech Tops up Series B to $28 Million

Why It Matters

The capital boost accelerates AI adoption in radiation oncology, promising faster, more personalized cancer care and opening sizable market opportunities for med‑tech investors.

Key Takeaways

• Lumonus raised total $28M Series B
• AI platform automates 75,000 radiation treatment plans
• Deployed across US, Australia, Europe
• Funding fuels US market expansion and product upgrades
• Clinicians consulted on 280,000 cancer treatments

Pulse Analysis

The oncology landscape is undergoing rapid digital transformation, with artificial intelligence emerging as a catalyst for more efficient radiation‑oncology workflows. Traditional treatment planning relies on manual calculations and fragmented data sources, creating bottlenecks that can delay patient care. AI‑driven platforms promise to streamline these processes, reduce human error, and enable personalized dose delivery. Investors have taken note, channeling capital into startups that can bridge the gap between cutting‑edge cancer biology and the operational realities of hospitals.

Lumonus, founded in 2024, has positioned itself at the forefront of this shift by delivering an end‑to‑end clinical‑care suite that automates both physician decision‑support (Lumonus AI Physician) and dosimetry calculations (Lumonus AI Dosimetry). The company’s technology is already active in the United States, Australia and Europe, where clinicians have consulted on more than 280,000 treatments and generated over 75,000 automated plans. The recent $3 million top‑up, bringing its Series B to $28 million, will accelerate U.S. go‑to‑market efforts, expand the clinical‑success team, and deepen its data‑analytics capabilities.

The infusion of capital underscores a broader investor confidence in AI‑enabled cancer care, a segment projected to exceed $10 billion by 2030. For health systems, adopting platforms like Lumonus can translate into faster treatment initiation, lower operational costs, and improved patient outcomes—key metrics in value‑based reimbursement models. As regulatory pathways for AI medical devices become clearer, companies that have already demonstrated real‑world efficacy will likely capture market share. Lumonus’s momentum suggests it could become a benchmark for scalable, data‑driven oncology solutions worldwide.